ORLANDO, FL, USA (UroToday.com) - Androgen deprivation therapy (ADT) improves disease-free survival in men with advanced prostate cancer, but patients develop castrate-resistant prostate cancer (CRPC), one of the causes of which is ineffective castration.
Total serum testosterone (T) does not accurately predict prostatic levels of T. Further reduction of androgens in men with CRPC can result in improvement of survival. Herein we compare the effects of GTx-758 an oral, selective estrogen receptor alpha (ERα) agonist, versus leuprolide on total and free (unbound) serum T levels in men with advanced prostate cancer....Click here to enlarge and view the poster.
(Click thumbnail to enlarge poster)
Presented by Evan Y. Yu,1 Marc Gittelman,2 Thomas E. Keane,3 Ronald Tutrone,4 Laurence Belkoff,5 Robert Given,6 Joel Bass,7 Franklin Chu,8 Mike Gambla,9 Franklin Gaylis,10 James Bailen,11 Robert H. Getzenberg,12 Christopher Coss,12 Michael L. Hancock,12 James T. Dalton,12 and Mitchell S. Steiner12 at the 2013 Genitourinary Cancers Symposium - February 14 - 16, 2013 - Rosen Shingle Creek - Orlando, Florida USA
1Univ. of Washington, Seattle, WA USA; 2South FL Medical Research, Aventura, FL USA; 3MUSC, Charleston, SC USA 4Chesapeake Urology, Towson, MD USA; Research Associates 5UCSEPA, Bala Cynwyd, PA USA; 6Urology of VA, PLLC, Virginia Beach, VA USA 7AMP of NY – Urology, Syracuse, NY USA; 8San Bernardino Urological Assoc., San Bernardino, CA USA; 9Central Urology Group, Columbus, OH USA 10Genesis Healthcare Partners, San Diego, CA USA; 11First Urology, PSC, Jeffersonville, IN USA; 12GTx, Inc., Memphis, TN USA
View Full 2013 GU Cancers Symposium Coverage